Where delivery transforms treatment.
Latus develops innovative gene therapy candidates that use precision delivery with the goal of improving the lives of patients.
The therapy isn’t just the gene — it's also the vehicle.
AAV (Adeno-Associated Virus) is a non-pathogenic virus commonly used in gene therapy to potentially deliver therapeutic genes to targeted cells. Traditional AAV approaches often face challenges due to a lack of potency and specificity, requiring high doses that lead to unwanted immune responses, tissue toxicities and difficulties with scalable manufacturing.
By screening tens of millions of novel capsid variants, we’re seeking to advance the standard for precision gene therapy.
Through deploying massively-paralleled, high throughput and unbiased screening of AAV capsids–we're mapping the course for the future of CNS treatment development. Designed to accurately target tissues and reduce unwanted interactions, our technology aims to minimize the risks of immunogenicity and toxicity, and to deliver the payload exactly where it's needed.
Pursuing Efficacy
Striving to Increase Substructure– and Cell-specific Targeting in the CNS
Prioritizing Well-Being
Aiming to Limit or Avoid On– and Off-Tissue Toxicity
Optimizing Administration
Designed for Direct Delivery with Conventional Clinical Techniques
Lead programs
Our one-time gene therapy candidates are designed to fundamentally change how many CNS diseases are treated.
Existing CNS treatment paradigms may require frequent administrations and have side effects that are sometimes worse than the disease. Our candidates are being designed to meaningfully reduce toxicity and improve quality of care for patients.
Huntington’s Disease
“HD remains a devastating, incurable genetic brain disease, for which we desperately need effective interventions. A breakthrough would be transformative for affected patients and families worldwide.”
—HD Clinician
CLN2
“I really hope we can find a way to slow down this disease. No parent wants to see their kid go through endless hospital visits, the pain of treatments, or spend their days in a hospital bed. We just want more happy, normal days at home, more laughter, and less tears—more time being a family without the constant stress of medical issues.”
—Caregiver
pipeline
The specificity of our capsids allows us to effectively target a broad range of CNS disorders.
AAV-EP+
Tissues of interest
Ependyma/neurons
Routes of Administration
icv
Targets
Lysosomal Storage Disorders
Secreted Protein
Cross-Correction
Secreted Protein Therapeutics
AAV-DB
Tissues of interest
Deep brain
Routes of Administration
ip
Targets
Parkinson’s Disease
Huntington’s Disease
AAV-Ear
Tissues of interest
Inner ear/hair cells
Routes of Administration
ICV
Targets
Genetic hearing loss
AAV-PN
Tissues of interest
Pan-neuronal
Routes of Administration
icv
Targets
Angelman Syndrome
Rett Syndrome
Frontotemporal dementia
Alzheimer’s Disease
AAV-CB
Tissues of interest
Cerebellum
Routes of Administration
icv, ip
Targets
Spinocereberal ataxias
Friedreich Ataxia
AAV-Vasc
Tissues of interest
Brain microvasculature
Routes of Administration
iv
Targets
Glut1 deficiency
Lysosomal Storage Disorders
Translational medicine expertise from pipette to patient.
Our team comprises industry-leading scientists, clinicians, and professionals dedicated to revolutionizing gene therapies for patients.
Leadership
.webp)
PArtners
Publications
Partners in Progress: Battling Huntington's with the HDF
Expanded Access Policy
Latus is committed to developing safe and effective therapies for patients and strives to put patients first. Our goal is to provide gene therapies to patients as soon as possible through efficient drug development.
At this time, Latus does not offer Expanded Access for our investigational gene therapies. Patients and health care providers who are interested in our investigational products may learn more about our applicable clinical trials, when available, by visiting clinicaltrials.gov and searching for Latus.
If you are a healthcare provider with questions about our clinical trials, please submit a request to: info@latusbio.com. We acknowledge questions as soon as possible, usually within 5 business days of receipt.
Latus will continue to evaluate expanded access opportunities as our efforts advance, and we reserve the right to update this policy at any time.
Gene therapy–precisely delivered.
Take a step forward in developing the next generation of potentially curative medicines for patients.